239 related articles for article (PubMed ID: 28622385)
21. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis.
Jouneau S; Bonizec M; Belleguic C; Desrues B; Brinchault G; Galaine J; Gangneux JP; Martin-Chouly C
PLoS One; 2011; 6(8):e22655. PubMed ID: 21826199
[TBL] [Abstract][Full Text] [Related]
22. Assessment of biofilm removal capacity of a broad host range bacteriophage JHP against Pseudomonas aeruginosa.
Shafique M; Alvi IA; Abbas Z; Ur Rehman S
APMIS; 2017 Jun; 125(6):579-584. PubMed ID: 28418081
[TBL] [Abstract][Full Text] [Related]
23. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation.
Mowat E; Rajendran R; Williams C; McCulloch E; Jones B; Lang S; Ramage G
FEMS Microbiol Lett; 2010 Dec; 313(2):96-102. PubMed ID: 20964704
[TBL] [Abstract][Full Text] [Related]
24. Pseudomonas phage inhibition of Candida albicans.
Nazik H; Joubert LM; Secor PR; Sweere JM; Bollyky PL; Sass G; Cegelski L; Stevens DA
Microbiology (Reading); 2017 Nov; 163(11):1568-1577. PubMed ID: 28982395
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.
Ferreira JA; Penner JC; Moss RB; Haagensen JA; Clemons KV; Spormann AM; Nazik H; Cohen K; Banaei N; Carolino E; Stevens DA
PLoS One; 2015; 10(8):e0134692. PubMed ID: 26252384
[TBL] [Abstract][Full Text] [Related]
26. Secondary Metabolites Produced during Aspergillus fumigatus and Pseudomonas aeruginosa Biofilm Formation.
Bastos RW; Akiyama D; Dos Reis TF; Colabardini AC; Luperini RS; de Castro PA; Baldini RL; Fill T; Goldman GH
mBio; 2022 Aug; 13(4):e0185022. PubMed ID: 35856657
[TBL] [Abstract][Full Text] [Related]
27. Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"?
Su S; Hassett DJ
Expert Opin Ther Targets; 2012 Sep; 16(9):859-73. PubMed ID: 22793158
[TBL] [Abstract][Full Text] [Related]
28. IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis.
Casaulta C; Schöni MH; Weichel M; Crameri R; Jutel M; Daigle I; Akdis M; Blaser K; Akdis CA
Pediatr Res; 2003 Feb; 53(2):313-9. PubMed ID: 12538792
[TBL] [Abstract][Full Text] [Related]
29. The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways.
Trend S; Fonceca AM; Ditcham WG; Kicic A; Cf A
J Cyst Fibros; 2017 Nov; 16(6):663-670. PubMed ID: 28720345
[TBL] [Abstract][Full Text] [Related]
30. Interaction between
Zhao J; Yu W
PeerJ; 2018; 6():e5931. PubMed ID: 30430043
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.
Saussereau E; Vachier I; Chiron R; Godbert B; Sermet I; Dufour N; Pirnay JP; De Vos D; Carrié F; Molinari N; Debarbieux L
Clin Microbiol Infect; 2014 Dec; 20(12):O983-90. PubMed ID: 24920209
[TBL] [Abstract][Full Text] [Related]
32. Tracking Polymicrobial Metabolism in Cystic Fibrosis Airways:
Gao B; Gallagher T; Zhang Y; Elbadawi-Sidhu M; Lai Z; Fiehn O; Whiteson KL
mSphere; 2018 Apr; 3(2):. PubMed ID: 29695623
[TBL] [Abstract][Full Text] [Related]
33. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
[TBL] [Abstract][Full Text] [Related]
34. Microenvironmental characteristics and physiology of biofilms in chronic infections of CF patients are strongly affected by the host immune response.
Jensen PØ; Kolpen M; Kragh KN; Kühl M
APMIS; 2017 Apr; 125(4):276-288. PubMed ID: 28407427
[TBL] [Abstract][Full Text] [Related]
35. Live imaging and quantitative analysis of
Wurster S; Sass G; Albert ND; Nazik H; Déziel E; Stevens DA; Kontoyiannis DP
Virulence; 2020 Dec; 11(1):1329-1336. PubMed ID: 33017225
[No Abstract] [Full Text] [Related]
36. Characterization of the integrated filamentous phage Pf5 and its involvement in small-colony formation.
Mooij MJ; Drenkard E; Llamas MA; Vandenbroucke-Grauls CMJE; Savelkoul PHM; Ausubel FM; Bitter W
Microbiology (Reading); 2007 Jun; 153(Pt 6):1790-1798. PubMed ID: 17526836
[TBL] [Abstract][Full Text] [Related]
37. Pseudomonas aeruginosa bacteriophage PA1Ø requires type IV pili for infection and shows broad bactericidal and biofilm removal activities.
Kim S; Rahman M; Seol SY; Yoon SS; Kim J
Appl Environ Microbiol; 2012 Sep; 78(17):6380-5. PubMed ID: 22752161
[TBL] [Abstract][Full Text] [Related]
38. The
Margalit A; Carolan JC; Sheehan D; Kavanagh K
Mol Cell Proteomics; 2020 Aug; 19(8):1346-1359. PubMed ID: 32447284
[TBL] [Abstract][Full Text] [Related]
39. Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis.
Shirazi F; Ferreira JA; Stevens DA; Clemons KV; Kontoyiannis DP
PLoS One; 2016; 11(3):e0150155. PubMed ID: 26930399
[TBL] [Abstract][Full Text] [Related]
40. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
